This HTML5 document contains 116 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n27http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01203/identifier/chemspider/
n13http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01203/identifier/chebi/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n9http://linked.opendata.cz/resource/drugbank/mixture/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01203/identifier/wikipedia/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01203/identifier/pharmgkb/
n31http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB01203/identifier/bindingdb/
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01203/identifier/pubchem-compound/
n30http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01203/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/drug/DB01203/identifier/kegg-drug/
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01203/identifier/drugbank/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01203/identifier/iuphar/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://www.drugs.com/cdi/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01203/identifier/guide-to-pharmacology/
n4http://linked.opendata.cz/resource/drugbank/property/
n25http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01203/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n32http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01203
rdf:type
n3:Drug
n3:description
A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. [PubChem]
n3:dosage
n26:271B554C-363D-11E5-9242-09173F13E4C5 n26:271B554D-363D-11E5-9242-09173F13E4C5 n26:271B554E-363D-11E5-9242-09173F13E4C5 n26:271B554F-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
14-24 hours
n3:indication
Used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension.
owl:sameAs
n30:DB01203 n31:DB01203
dcterms:title
Nadolol
adms:identifier
n11:25766 n14:46505509 n15:PA450573 n16:39147 n17:DB01203 n18:Nadolol n19:7444 n20:35815 n21:D00432 n22:0378-0028-01 n23:554 n24:554
n3:mechanismOfAction
Like other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Nadolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
n3:packager
n8:271B553B-363D-11E5-9242-09173F13E4C5 n8:271B5539-363D-11E5-9242-09173F13E4C5 n8:271B553A-363D-11E5-9242-09173F13E4C5 n8:271B5537-363D-11E5-9242-09173F13E4C5 n8:271B5538-363D-11E5-9242-09173F13E4C5 n8:271B5535-363D-11E5-9242-09173F13E4C5 n8:271B5536-363D-11E5-9242-09173F13E4C5 n8:271B552B-363D-11E5-9242-09173F13E4C5 n8:271B552C-363D-11E5-9242-09173F13E4C5 n8:271B5529-363D-11E5-9242-09173F13E4C5 n8:271B552A-363D-11E5-9242-09173F13E4C5 n8:271B5527-363D-11E5-9242-09173F13E4C5 n8:271B5528-363D-11E5-9242-09173F13E4C5 n8:271B5525-363D-11E5-9242-09173F13E4C5 n8:271B5526-363D-11E5-9242-09173F13E4C5 n8:271B5533-363D-11E5-9242-09173F13E4C5 n8:271B5534-363D-11E5-9242-09173F13E4C5 n8:271B5531-363D-11E5-9242-09173F13E4C5 n8:271B5532-363D-11E5-9242-09173F13E4C5 n8:271B552F-363D-11E5-9242-09173F13E4C5 n8:271B5530-363D-11E5-9242-09173F13E4C5 n8:271B552D-363D-11E5-9242-09173F13E4C5 n8:271B552E-363D-11E5-9242-09173F13E4C5 n8:271B5523-363D-11E5-9242-09173F13E4C5 n8:271B5524-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Unlike many other beta-adrenergic blocking agents, nadolol is not metabolized by the liver and is excreted unchanged, principally by the kidneys. Nadolol is excreted predominantly in the urine.
n3:synonym
Corgard
n3:toxicity
Oral, mouse: LD<sub>50</sub> = 4500mg/kg. Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.
n12:hasAHFSCode
n13:24-24-00
n3:foodInteraction
Take without regard to meals. Avoid alcohol. Magnesium, potassium and zinc needs increased. Avoid natural licorice.
n3:mixture
n9:271B5521-363D-11E5-9242-09173F13E4C5 n9:271B5522-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
30%
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Nadolol.htm
foaf:page
n7:nadolol.html n25:cor1102.shtml n27:nadolol.htm
n3:IUPAC-Name
n4:271B5554-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B555A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5559-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5556-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5557-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5558-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5552-363D-11E5-9242-09173F13E4C5 n4:271B556A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5553-363D-11E5-9242-09173F13E4C5 n4:271B5550-363D-11E5-9242-09173F13E4C5 n4:271B556C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5551-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B556E-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n32:C07AA12
n3:H-Bond-Acceptor-Count
n4:271B5560-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5561-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B555B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B555C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B555E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B555D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B555F-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorption of nadolol after oral dosing is variable, averaging about 30 percent.
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n4:271B556D-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
42200-33-9
n3:containedIn
n5:271B553C-363D-11E5-9242-09173F13E4C5 n5:271B553D-363D-11E5-9242-09173F13E4C5 n5:271B5545-363D-11E5-9242-09173F13E4C5 n5:271B5546-363D-11E5-9242-09173F13E4C5 n5:271B5543-363D-11E5-9242-09173F13E4C5 n5:271B5544-363D-11E5-9242-09173F13E4C5 n5:271B5541-363D-11E5-9242-09173F13E4C5 n5:271B5542-363D-11E5-9242-09173F13E4C5 n5:271B554B-363D-11E5-9242-09173F13E4C5 n5:271B5549-363D-11E5-9242-09173F13E4C5 n5:271B554A-363D-11E5-9242-09173F13E4C5 n5:271B5547-363D-11E5-9242-09173F13E4C5 n5:271B5548-363D-11E5-9242-09173F13E4C5 n5:271B5540-363D-11E5-9242-09173F13E4C5 n5:271B553E-363D-11E5-9242-09173F13E4C5 n5:271B553F-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5566-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5568-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5569-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B556B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5565-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5564-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5567-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5555-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5562-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5563-363D-11E5-9242-09173F13E4C5